

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

NCI-H1299

RRID:CVCL_0060

Type: Cell Line

Proper Citation

RRID:CVCL_0060

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0060

Proper Citation: RRID:CVCL_0060

Description: Cell line NCI-H1299 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung large cell carcinoma

Defining Citation: [PMID:1311061](#), [PMID:1563005](#), [PMID:1565469](#), [PMID:8806092](#), [PMID:11030152](#), [PMID:12068308](#), [PMID:17332333](#), [PMID:18083107](#), [PMID:19153074](#), [PMID:19472407](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:20679594](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:24335698](#), [PMID:25485619](#), [PMID:25714623](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:26929325](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:30038707](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:34737324](#), [PMID:35839778](#), [PMID:36264037](#)

Comments: Karyotypic information: Has lost chromosome Y (PubMed=25714623)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H1299

Synonyms: H1299, H-1299, NCIH1299

Cross References: BTO:BTO_0002552, CLO:CLO_0007986, EFO:EFO_0003043, MCCL:MCC:0000352, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5803, BCRJ:0185, BioGRID_ORCS_Cell_line:234, BioSample:SAMN03471642, BioSample:SAMN03471739, BioSample:SAMN10988385, cancercellines:CVCL_0060, CCRID:1101HUM-PUMC000469, CCRID:1102HUM-NIFDC00050, CCRID:3101HUMSCSP589, CCRID:3101HUMTCHu160, CCRID:4201HUM-CCTCC00640, Cell_Model_Passport:SIDM00649, ChEMBL-Cells:ChEMBL3308501, ChEMBL-Targets:ChEMBL612255, CLS:300485, Cosmic:722069, Cosmic:724831, Cosmic:877265, Cosmic:877418, Cosmic:903585, Cosmic:961838, Cosmic:980971, Cosmic:1004693, Cosmic:1032443, Cosmic:1047106, Cosmic:1066159, Cosmic:1146875, Cosmic:1154606, Cosmic:1175867, Cosmic:1218870, Cosmic:1239925, Cosmic:1609524, Cosmic:1870264, Cosmic:1925845, Cosmic:1995520, Cosmic:2042873, Cosmic:2125178, Cosmic:2630419, Cosmic:2664126, Cosmic:2749161, Cosmic:2772159, Cosmic-CLP:724831, DepMap:ACH-000510, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:724831, GEO:GSM108807, GEO:GSM108808, GEO:GSM185871, GEO:GSM206471, GEO:GSM253382, GEO:GSM274743, GEO:GSM274744, GEO:GSM353229, GEO:GSM434266, GEO:GSM784253, GEO:GSM794311, GEO:GSM817080, GEO:GSM827467, GEO:GSM844617, GEO:GSM887355, GEO:GSM888433, GEO:GSM1374698, GEO:GSM1374699, GEO:GSM1670165, IARC_TP53:21537, IARC_TP53:21722, IGRhCellID:H1299GEO, KCB:KCB2021017YJ, KCLB:25803, KCLB:91299, LiGeA:CCL_300, LINCS_LDP:LCL-1609, Lonza:796, MetaboLights:MTBLS873, NCI-DTP:NCI-H1299, PharmacDB:NCIH1299_1006_2019, PRIDE:PXD003743, PRIDE:PXD005291, PRIDE:PXD018581, PRIDE:PXD030304, PRIDE:PXD035746, Progenetix:CVCL_0060, PubChem_Cell_line:CVCL_0060, TOKU-E:2592, TOKU-E:3620, Ubigen:YC-D010, Wikidata:Q5628772

ID: CVCL_0060

Record Creation Time: 20220427T220837+0000

Record Last Update: 20260829T234740+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H1299.

No alerts have been found for NCI-H1299.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6404 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Xu D, et al. (2026) Nanoreactor-enabled PANoptosis via ZBP1 activation potentiates immunotherapy in non-small cell lung cancer. *Biomaterials*, 328, 123894.

Mao C, et al. (2026) DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer. *Cancer research*, 86(13), 3309.

Ge Y, et al. (2026) MTFR2 promotes VDAC1 oligomerization to reprogram BCAA metabolism in tumor cells to polarize TAMs in LUAD. *Cell death & disease*.

Chen Y, et al. (2026) PFKFB4 Deubiquitination by USP10 Enhances Fumarate Metabolism to Orchestrate the KDM1A/Rad51 Axis and Confer Radioresistance in Lung Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e76439.

Zhao X, et al. (2026) Deep learning reveals FLAD1-mediated mitochondrial metabolic reprogramming in hypoxic tumors. *Cell reports*, 45(7), 117711.

Wang Z, et al. (2026) DCAF12 Ubiquitin Ligase Promotes Lung Cancer Metastasis by Modulating the TRiC/CCT Chaperonin Complex. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(3), e09695.

Pan K, et al. (2026) Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy. *Biochemical pharmacology*, 243(Pt 2), 117562.

Zhang J, et al. (2026) Tumor-associated macrophages educated by IGSF9 exhibit a senescence-associated secretory phenotype to promote tumor immune escape. *Journal for immunotherapy of cancer*, 14(1).

Deng H, et al. (2026) IRF3 attenuates hypoxia signaling by retaining HIF- α in the cytoplasm. *Cell reports*, 45(1), 116815.

Xu X, et al. (2026) Pro-ATO/Allicin Liposomes for Dual-Pathway Targeting of p53-Mutant Tumors. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(18), e19194.

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD⁺ to eradicate KRAS-driven AML. *Cell metabolism*, 38(6), 1113.

Będzińska A, et al. (2026) The p53 tumor suppressor modulates the expression of proteins that control natural killer cell activity. *Cell communication and signaling : CCS*, 24(1).

Pu Y, et al. (2026) TEAD1 Enhances Exosome Secretion and Promotes Exosome-Mediated Tissue Regeneration. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(25), e14104.

Kim JW, et al. (2026) Methionine metabolism is linked with phospholipid and glutamine metabolism to drive ferroptosis. *Cell reports*, 45(4), 117157.

Ma X, et al. (2026) UFMylation-dependent inhibition of AKT signaling by PHLDA3 in lung adenocarcinoma. *Cell reports*, 45(4), 117154.

Wang Y, et al. (2026) Targeting SERPINE1 enhances PD-1 blockade response by modulating macrophage infiltration and polarization through the STAT3-CCL2 axis in non-small cell lung cancer. *International immunopharmacology*, 178, 116577.

Zhang Y, et al. (2026) Targeting IRF1-TRIM21 axis enhances anti-tumor immunity by promoting ubiquitin-mediated degradation of FGL1 in non-small cell lung cancer. *Communications biology*, 9(1).

Fujiyama H, et al. (2026) Diamond-Blackfan anemia gene product RPS19 counteracts SET to maintain p53 transcriptional activity and tumor suppressor function. *Cell reports*, 45(5), 117333.

Wu P, et al. (2026) SARS-CoV-2 N Protein Hijacks the m6A Reader YTHDF2 to Suppress Antiviral Gene Expression. *Viruses*, 18(5).

Pantazaka E, et al. (2026) Repurposing Artesunate to Combat Progression and Metastasis via Targeting Circulating Tumor Cells. *Oncology research*, 34(6), 13.